Please login to the form below

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

Mylan, Biocon’s Herceptin biosimilar launched in US

To counteract the onslaught from these biosimilars, Roche has prepped filings for a fixed-dose combination of both Herceptin and its other antibody blockbuster Perjeta (pertuzumab), promising simpler dosing of the ... minutes. Currently, Herceptin and

Latest news

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta. Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average ... The key drugs which have been added to the list include
Seattle Genetics preps filing next year for oral HER2 drug

Herceptin plus Xeloda is a standard regimen for HER2-positive breast cancer in patients previously treated with Herceptin and Roche’s other HER2-targeting drugs Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab
AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Although it has crossed the blockbuster threshold this year, Kadcyla is still the runt of Roche’s HER2 litter lagging well behind Herceptin (trastuzumab) and Perjeta (pertuzumab) in sales terms. ... in order to move it into earlier lines of treatment
Roche reports continued growth in Q3, despite biosimilar competition

According to the Swiss pharma, the key drivers of this growth were mutliple sclerosis medicine Ocrevus, new haemophilia treatment Hemlibra and its cancer medicines – Tecentriq, Perjeta and Avastin. ... The sales increase in US stood at 14%, led by
SMC approves Yescarta and Keytruda, rejects Perjeta

sales. Not-so-lucky was Roche’s Perjeta (pertuzumab), which has been handed a rejection by the SMC. ... Perjeta has patent protection until 2023 in Europe and 2024 in the US, so Roche will be hoping to continue to push the drug into new areas and

More from news
Approximately 20 fully matching, plus 49 partially matching documents found.

Latest Intelligence

The Cystic Fibrosis Buyers’ Club

cancer drug Perjeta.
Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Genentech’s Perjeta (pertuzumab). due to lack of sufficient evidence to demonstrate a clinically meaningful overall survival benefit in early-stage disease.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word: ...